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Septic shock is mediated by complex interactions of cells, cytokines, and humoral pathways.
Clinical therapeutic strategies aimed at inhibiting selected pathways have been efficacious in
subsets of patients. Experimental studies focusing on the activities of single cytokines have
contributed to the understanding of the complex pathophysiology of septic shock. More precise
delineation of the roles of each mechanism contributing to pathogenesis will permit the identifi-
cation of subsets of patients who might benefit from particular therapeutic strategies and will
guide the development of additional approaches to prevention and treatment.
Septic shock is a clinical syndrome that has become in-
creasingly important in the last 40 years. The condition is
most common among hospitalized patients, particularly
those with underlying diseases. Although patients with dis-
eases caused by "classic" gram-negative pathogens (such as
plague or typhoid fever) may present with the clinical picture
of septic shock, it is only since the I950s-with the increas-
ing incidence of disease caused by gram-negative bacilli of
the normal host flora-that the sepsis/septic shock syn-
dromes have been defined. We believe that these definitions
(table I) [I, 2] are satisfactory: the identical incidences of
shock and death in the various clinical studies using these
criteria indicate that similar groups of patients are being
enrolled. However, the definitions need to be improved to
take into account various factors that are important for pre-
dicting outcome, including underlying diseases and appropri-
ateness ofantibiotic and medical/surgical treatment. A modi-
fied scheme for classification of these syndromes-known as
systemic inflammatory response syndrome (SIRS) and multi-
ple organ dysfunction syndrome (MODS) [3]-is currently
being discussed, but no consensus has yet been reached.
Septic shock has traditionally been recognized as a conse-
quence of gram-negative bacterial infection, but it may also
be caused by gram-positive organisms and fungi and proba-
bly by viruses and parasites as well. Table 2 summarizes the
organisms isolated and the mortality documented in three
recent studies of sepsis syndrome/septic shock [2, 4, 5].
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Gram-negative bacteria were isolated in 30%-80% of cases
and gram-positive bacteria in 5%-24%. In one prospective
study of sepsis syndrome [2], no etiologic agent was identi-
fied in more than half of all cases. Notably, the severity of
septic shock, as reflected by mortality, did not depend on the
type of organism responsible.
Initial studies of the pathophysiological features of septic
shock concentrated on the interactions oflipopolysaccharide
(LPS) from the gram-negative bacterial cell wall with various
humoral pathways. However, attention is now focused on
the central role of macrophages, endothelium, and cytokines
that are released upon stimulation by most if not all of the
recognized agents of septic shock (figure I). In this review,
we address the known humoral pathways that are activated
during septic shock, and we discuss the role of cytokines,
particularly tumor necrosis factor (TNF) and interleukin I
(IL-I ). Although the current emphasis is on the activation of
macrophages and cytokine production, we think that evi-
dence for direct activation of humoral pathways by microbial
constituents remains relevant. We also review the mecha-
nisms by which LPS interacts with macrophages, citing exper-
imental and clinical studies evaluating the potential of anti-
LPS and anticytokine agents in therapy for septic shock.
Bacterial Cell-Wall Components and Septic Shock
The exotoxins produced by some bacteria (e.g., exotoxin
A produced by Pseudomonas aeruginosa or toxic shock syn-
drome toxin produced by some strains ofStaphylococcus aur-
eus) can initiate septic shock. However, the bacteria them-
selves-and in particular their cell wall components-are
primarily responsible for the development of septic shock.
These components are potent activators of numerous hu-
moral pathways and also of macrophages and other cells in-
volved in inflammatory processes.
The prime initiator ofgram-negative bacterial septic shock
is endotoxin, an LPS component of the bacterial outer mem-
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Table I. Definitions of sepsis syndrome and septic shock.
Sepsis syndrome
Clinical evidence of infection
Tachypnea*
Tachycardia"
Hyperthermia or hypothermia!
Evidence of inadequate organ perfusion.
including one or more of the
following:
Hypoxemia'
Elevated plasma lactate concentration''
Oliguria"
Septic shock
Sepsis syndrome with
hypotension**
bacteria. Internal to the a side chains are the core oligosac-
charides, which have similar structures in common gram-
negative bacteria. Lipid A, which is bound to the core oligo-
saccharide, has a highly conserved structure and is
responsible for most of the toxicity of endotoxin. However,
some types ofnatural lipid A and synthetic lipid A analogues
that have different sugar and acyl residues are less-or not at
all-toxic both in vitro and in vivo. This observation has led
to the development of lipid A analogues that can block the
toxic effects of endotoxin or act as endotoxin antagonists
[8, 9].
* Respirations. >20/min; if mechanically ventilated. > 10 L/min.
t Pulse. >90/min.
*Core or rectal temperature. >38.3°C or <35.6°C.
, Pao2/FI02. ~280 (without other pulmonary or cardiovascular disease as
the cause).
II Exceeding upper limits of normal for the laboratory.
# Documented urine output. <0.5 mL/kg of body weight for at least I
hour (in patients with catheters).
**Sustained decrease in systolic blood pressure to <90 mm Hg or drop by
>40 mm Hg for at least I hour when volume replacement is adequate. the
patient is taking no antihypertensive medication. and other causes of shock
(such as hypovolemia. myocardial infarction. and pulmonary embolism) are
absent.
brane. Endotoxin circulating in the blood appears to be a
predictor of poor outcome in some clinical settings (e.g.,
meningococcemia [6]), but the levels of endotoxin required
to trigger the cascade of events in septic shock may vary
greatly. Indeed, it has been observed that bacterial products
other than LPS may profoundly increase the host's sensitivity
to endotoxin, thereby rendering toxic otherwise-harmless lev-
els [7]. Hence, the measurement of endotoxin has not yet
become standard clinical practice.
The outermost part of the endotoxin molecule consists of
a series of structurally and antigenically diverse oligosaccha-
rides that are responsible for the a serotype ofgram-negative
Antibodies to Endotoxin
The a-specific oligosaccharide side chains of endotoxin
are highly immunogenic. Antibodies to these side chains in-
hibit the effects of endotoxin and, by virtue of their opsono-
phagocytic properties, eradicate the endotoxin-producing or-
ganism. However, because these antibodies are specific for a
particular 0 serotype, their clinical application is limited. An
alternative approach has been to develop antibodies to the
structurally conserved core glycolipid of endotoxin or to
lipid A in the hope that these antibodies will offer cross-reac-
tivity or cross-protection against the toxic component of all
gram-negative bacteria. In initial clinical trials conducted 10
years ago, antisera or preparations of hyperimmune polyclo-
nal intravenous immunoglobulin were used (l 0-13]. While
the results of these trials suggested a benefit and stimulated
subsequent trials ofmonoclonal antibodies, they did not spe-
cifically demonstrate that antibodies to lipid A were responsi-
ble for the protection observed.
Recently, clinical trials of two monoclonal antibodies to
the core glycolipid of endotoxin have received considerable
attention [14, 15]. In a prospective, randomized, placebo-
controlled trial ofE5 (a murine monoclonal IgM antibody to
lipid A), 486 patients with suspected gram-negative sepsis
Table2. Frequency ofisolation ofvarious types of microorganisms and corresponding mortality in
three recent studies of sepsis syndrome/septic shock.
Frequency of isolation/mortality among
patients with indicated condition*
Type of microorganism
Gram-negative bacteria
Gram-positive bacteria
Mixed or fungi
Not documented
Total
* Figures are percentages.
t Data are from [2].
*Data are from [4].
'Data are from [5].
Sepsis syndromet
(n = 382)
30/31
16/29
3/5
53/30
100/30
Septic shockl
(n = 119)
60/49
24/89
16/75
100/63
Septic shock'
(n = 89)
80/55
5/2
4/2
10/11
100/47
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Figure 1. Interaction of humoral factors and cytokinesin the pathogenesis of septicshock.LPS = lipopolysaccharide; LBP= LPS-binding
protein; PA-INHI = plasmin activator-inhibitor I; DIe = disseminated intravascular coagulation; ARDS = adult respiratory distress
syndrome;NO = nitric oxide; and MOF = multiple organ failure.
received either placebo or two intravenous doses of E5 (2
mg/kg) 24 hours apart [14]. The two groups of patients were
reasonably well matched, although the unavailability of
scores on the Acute Physiologic and Chronic Health Exami-
nation (APACHE) II for 203 patients represented a poten-
tially important source ofbias. Of the 468 evaluable patients,
316 had a documented gram-negative infection; 179 of these
316 patients presented with shock. Among the 137 patients
who did not present with shock, treatment with E5 was asso-
ciated with significantly lower 30-day mortality (P = .03)
and with significantly more frequent resolution of major
morbidities (i.e., complications of shock such as dissemi-
nated intravascular coagulation [DIC] and acute renal fail-
ure) (P = .04) than was placebo administration. However, no
differences in mortality were found between E5-treated pa-
tients and placebo recipients who presented with shock or
between E5-treated patients and placebo recipients who did
not have gram-negative sepsis. Administration of E5 was
found to be safe; it did cause an increase in the level of anti-
body to murine immunoglobulin in approximately one-half
of patients, but the titer was usually low and of no clinical
importance.
Since this study suggested that E5 was effective in a sub-
group of patients defined retrospectively, a second multi-
center study was conducted to verify the finding prospec-
tively. A total of 847 patients without shock were enrolled.
The favorable results of the first study were not confirmed:
treatment with E5 did not affect survival among the 530
patients with documented gram-negative sepsis. However,
a favorable-albeit statistically insignificant-trend was
noted in the subgroup of patients in whom gram-negative
sepsis was associated with major morbidities, such as DIe
and renal failure [16]. A third trial of E5 is under way.
A clinical trial was also performed with HA-I A, a human
monoclonal antibody to lipid A. In a study similar in design
to that described for E5, patients with suspected gram-nega-
tive infection were randomized to receive either an albumin
placebo or a single 100-mg intravenous dose ofHA-1 A [15].
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Of 543 patients enrolled in the study, 317 had microbiologi-
cally documented gram-negative infections; 117 of these 317
patients had had sterile blood cultures at randomization.
HA-l A did not reduce mortality either in the overall study
population or in the 117 patients with nonbacteremic gram-
negative infections. However, mortality did decrease with
treatment among the 200 patients with gram-negative bacter-
emia (P = .014). While this difference in mortality was also
noted among the 101 patients with gram-negative bacter-
emia who presented with shock at enrollment, no such differ-
ence was found among the 99 patients with gram-negative
bacteremia who did not present with shock. These data con-
trast with the findings from the first study of E5, in which
patients appeared to be protected whether or not they were
bacteremic but only when they were not in shock.
This report of reduced mortality in a subgroup of patients
given HA-l A led to the licensure of the product in some
European countries. However, in the United States, the
Food and Drug Administration did not approve this product
for several reasons, including (1) changes in the protocol
during the clinical trial; (2) the documentation of significant
differences only in subgroups of patients; and (3) possible
imbalances favoring the test drug at randomization of the
patients [17]. Therefore, a second study that focused on pa-
tients with gram-negative bacteremia and shock was initi-
ated. During this trial the manufacturer voluntarily withdrew
HA-l A from the market in Europe because ofexcess mortal-
ity in patients without gram-negative bacteremia [18].
These disappointing results with the two monoclonal anti-
bodies to lipid A are, perhaps, not totally unexpected in light
of the studies that led to their development. First, in the
original experiments testing the hypothesis that cross-protec-
tion could be provided by antibodies to core glycolipid of
endotoxin, killed bacteria from a rough-cell-wall mutant
strain of Escherichia coli 0 III (strain 15) were used for the
immunization of animals or humans in order to obtain poly-
clonal antisera. Although some studies showed protection
with polyclonal antisera to 15, it was impossible to show
definitively that protection was attributable to cross-protec-
tive antibodies. Indeed, a favorable outcome could not be
correlated with antibody titers in either of the two clinical
studies done with human polyclonal antisera to 15 ([ 10, 11]
and 1. D. Baumgartner, unpublished data). By solubilization
of the core glycolipid in a physiological manner to circum-
vent nonspecific binding [19], the 15 antisera used in one
study were later shown to contain IgG and IgM antibody to
15 at a titer only threefold higher than that in control (preim-
mune) serum; furthermore, these antisera contained no more
antibodies to lipid A than did the control serum [20]. More-
over, it now appears that antibodies to 15 are highly specific
for E. coli15 and that they do not cross-react with endotoxin
from other bacteria. Hence, the mechanisms ofprotection by
antisera to 15 remain unknown. Nevertheless, this approach
with polyclonal sera raised against rough structures of LPS
laid the groundwork for the development of therapeutic
monoclonal antibodies to core glycolipid.
Second, it now appears that clinical trials with these mono-
clonal antibodies to lipid A were initiated before the immu-
nologic reactivity of these antibodies for LPS substructures
was recognized. Since the first disclosure of the possible effi-
cacy ofE5 and HA-l A in patients with septic shock [14, 15],
many studies have been undertaken to define the reactivity
of these antibodies for LPS. In studies by Fujihara et al. [21]
and Mascelli et al. [22], HA-l A reportedly bound to lipid A,
rough LPS structures, and some preparations ofsmooth LPS;
however, Baumgartner could not confirm such reactivity
[23]. Thus the specificity of these antibodies for lipid A is
uncertain, in part because immunoglobulins-especially
those of the IgM isotype-tend to bind nonspecifically to
both the highly amphophilic core oligosaccharide ofLPS and
lipid A molecules.
It has also been suggested that HA-IA lowers levels of
endotoxin by mediating the clearance of LPS via comple-
ment-dependent binding ofLPS to complement receptor ex-
pressed on erythrocytes and neutrophils [24, 25]. Similarly,
E5 was shown to bind to lipid A, to rough LPS, and to 15
preparations of smooth LPS isolated from various strains of
gram-negative bacteria [26, 27]. However, neither HA-lA
nor E5 was able to neutralize LPS in vitro, as assessed by the
limulus lysate test, by a mitogenic assay for murine spleno-
cytes, or by measurement of the production of cytokines in
human whole blood [28].
Studies with HA-l A in vivo have yielded inconclusive re-
sults. Initially, HA-lA was reported to be protective in mice
when used unpurified (as hybridoma fluid) [29]; however, a
purified monoclonal antibody obtained from the same clone
was not protective in similar experiments and did not sup-
press endotoxin-induced production of TNF in vivo [30]. A
similar failure of HA-lA to protect mice from LPS-induced
death was recently reported [31]. More important, in recent
experiments with dogs, HA-lA did not alter levels of'bacter-
emia or endotoxemia and was actually associated with a de-
creased rate of survival [32]. E5, initially studied in vivo by
Young et al. [33], was subsequently shown to be beneficial in
a model of pseudomonas sepsis in neutropenic mice [34].
The discrepancies in these results of in vitro and in vivo
studies stressed the need for extensive characterization of
antibodies to core glycolipid before the initiation of clinical
trials.
Activation of Pathways Other Than Cytokines by Cell
Wall Components
Numerous humoral mediators of sepsis have been identi-
fied so far, and it is likely that more will be discovered. These
mediators act through complex synergistic and antagonistic
interactions. LPS in the blood activates the coagulation and
complement cascades and induces a broad array ofmediators
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from macrophages and other cells, including endothelial
cells.
The alternative complement pathway can be activated ex-
perimentally by LPS and gram-positive bacterial cell-wall
components. The classic pathway is activated mainly by
complexes of cell wall components and antibodies. The ana-
phylatoxins C3a and C5a, which are produced as a result of
activation of these pathways, are responsible for a series of
inflammatory events that have been implicated in the patho-
physiology of septic shock. C5a has been directly associated
with TNF and LPS in hemorrhagic necrosis [35]. Comple-
ment components induce vasodilation and increased vascu-
lar permeability, which can result in hemodynamic changes,
aggregation of platelets, and aggregation and activation of
neutrophils-all processes that have been implicated in the
pathogenesis of the adult respiratory distress syndrome [36].
The subsequent release ofarachidonic acid derivatives, cyto-
toxic products of molecular oxygen, and lysosomal enzymes
exerts additional local vasoactive effects on the microvascula-
ture and causes endothelial cell cytotoxicity, which results in
capillary leakage. An increased concentration of activated
complement has been associated with a fatal outcome in
septic shock of both gram-positive and gram-negative
origin [37J.
It is well known that arachidonic acid metabolites cause
vasodilation, platelet aggregation, and neutrophil activation,
which may contribute to the pathogenesis of septic shock.
These substances are found in increased concentrations after
experimental challenge with endotoxin and during septic
shock in patients [38J. The role of inhibitor/antagonists of
the pathways of arachidonic acid metabolism in the treat-
ment of septic shock is being investigated.
Activated neutrophils, a key element in the inflammatory
response, probably play an important part in the pathogene-
sis ofseptic shock by contributing to vascular and tissue inju-
ries. Strong evidence indicates that neutrophils are activated
either directly by LPS or indirectly through the action of
cytokines [39]. As a result, activated neutrophils may dam-
age tissues by releasing oxygen metabolites and lysosomal
enzymes, or they may cause microemboli after aggregation.
Activated leukocytes adhere to one another, to endothelial
cells, and to tissues through interactions of receptors (on en-
dothelial cells) and ligands (on inflammatory cells) that are
mediated by specific adhesion molecules (figure 2). The ad-
hesion process is essential to most functions of leukocytes
(including chemotaxis, phagocytosis, and cytotoxicity [40]),
and blocking ofthe adhesion process by monoclonal antibod-
ies prevents tissue injury and improves the survival rate in
animal models of septic shock [41].
Two humoral factors are currently being evaluated for
their role as mediators ofseptic shock: platelet-activating fac-
tor (PAF) and nitric oxide (NO). The infusion of endotoxin
induces the release of PAF, a potent phospholipid mediator
that leads to autocatalytic amplification of cytokine release.
PAF is a mediator of inflammation caused by macro phages,
neutrophils, platelets, and endothelial cells in response to
injury (figure 2). Elevated levels ofPAF have been found in
models of endotoxin-induced hypotension and endotoxin-
induced lung injury in rats [42, 43]. Many antagonists to
PAF exist [44]. The first data from a randomized clinical trial
of the efficacy of a PAF antagonist in severe sepsis have re-
cently been reported [45]. In this study 262 patients received
either placebo or the PAF antagonist. Mortality decreased by
42% with PAF antagonist treatment in a subset of 119 pa-
tients with documented gram-negative sepsis (57% vs. 33%; P
= .011). A confirmatory study focusing on gram-negative
sepsis is now in progress.
Hypotension during septic shock may reflect increased syn-
thesis of the potent vasodilator NO. Considerable informa-
tion is now available on the activity of NO in vitro [46].
Upon LPS challenge, NO is produced mainly by macro-
phages, endothelial cells, smooth muscle cells, and the liver.
Although LPS-induced release of NO by macrophages ap-
pears to take several hours, endothelial cells react within min-
utes-a phenomenon that may contribute to the rapid de-
crease in blood pressure associated with endotoxic shock
[47]. An increasing number of reports deal with the inhibi-
tion of this pathway in animal models, but the precise role of
NO in septic shock remains unclear [48]. Activity of NO has
been detected in experimental gram-negative sepsis [49] and
in patients with the sepsis syndrome [50]. While NO block-
ade in animals has been reported to be beneficial in some
studies [51, 52], it has also been found to be detrimental
[53]. Treatment with N-monomethyl-L-arginine, which
blocks NO synthesis, transiently restored blood pressure and
systemic vascular resistance in two patients in whom conven-
tional therapy failed [54]. While NO has potentially deleteri-
ous effects in endotoxemia, a critical level of locally pro-
duced NO is needed to maintain vascular tone. Therefore,
more experimental and clinical studies must explore the role
ofNO in septic shock and delineate the potential for its inhi-
bition in patients.
Factor XII (Hageman factor) in the coagulation cascade
has long been known to playa central role in the pathogene-
sis of septic shock. It is activated equally efficiently by pepti-
doglycan residues and teichoic acid from the cell wall of
gram-positive organisms-e.g., S. aureus and streptococci
(including pneumococci)-and by LPS and lipid A from
gram-negative bacilli [55, 56]. Through activation of Factor
XI, activated Factor XII triggers the production of tissue fac-
tor both by the intrinsic coagulation pathway and by endothe-
lial cells and macrophages; in turn, tissue factor activates the
extrinsic coagulation pathway (figures 1 and 2). The activa-
tion of these pathways through these various stimuli may
lead to consumption of coagulation factors and Ole. More-
over, the activation of the contact system by LPS-activated
Factor XII (i.e., activation of Factor XII when it comes in
contact with negatively charged surfaces, such as those of
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Figure 2. Experimental approaches to blocking septic shock. (A) Monoclonal antibodies to LPS prevent LPS from activating inflamma-
tory reactions. (B) Bactericidal/permeability-increasing protein (BPI), a protein from neutrophil granules, binds LPS. Neither BPI nor
antibodies to LPS function when gram-positive organisms invade the bloodstream. (C) TNF-a is inhibited by antibodies or soluble TNF-a
receptors. (D) IL-I is blocked by soluble IL-I receptors or IL-I receptor antagonist (IL-I ra), a naturally occurring human protein. (E) Tissue
damage later in the septic shock cascade is minimized by protease inhibitors and free-radicalscavengersor agents blocking other cytokines,
including IL-6 and IL-8. LBP = LPS-binding protein; PAF = platelet-activating factor; NO = nitric oxide; and SCDl4 = soluble CDI4.
organisms or substances) results in the conversion of prekal-
likrein to kallikrein. In turn, kallikrein cleaves high-molecu-
lar-weight kininogen to release bradykinin, a potent hypo-
tensive agent [57]. The hypotension and DIC of bacteremia
may be mediated-at least in part-by the activation of the
contact system via the release of bradykinin and the activa-
tion of Factor XI. Recently, a monoclonal antibody to Fac-
tor XII was used to block contact activation in baboons; the
results showed that the contact system contributes to hypo-
tension but not to DIC in lethal bacteremia [58]. The fact
that tissue factor produced upon stimulation ofmacrophages
and endothelial cells by LPS plays a major role in inducing
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DIC is indicated by the prevention of LPS-induced DIC by
antibody to tissue factor in animals [59, 60]. Evidence also
exists that protein C can be activated during gram-negative
bacteremia [61] and that activated protein C can prevent the
coagulopathic and lethal effects of E. coli infusion in ba-
boons [62].
Finally, it is widely recognized that vascular endothelium
plays an active role in the development of septic shock. The
systemic effects of high doses of intravenously administered
TNF or IL-l into animals include hypotension, decreased
systemic vascular resistance, vascular leak, and infiltration of
polymorphonuclear leukocytes (PMNs) into tissues [63]. En-
hancement ofthe expression ofadhesion molecules on endo-
thelial cells by TNF and IL-l facilitates PMN margination.
TNF and IL-l increase the procoagulant activity of endothe-
lium and depress the expression of fibrinolytic activity; these
changes result in a trend towards intravascular coagulation
[64]. Generally, in animals given antibody to TNF or IL-l
receptor antagonist (IL-l ra), an attenuation and/or blockade
of many pathophysiological changes is associated with acti-
vation of the coagulation cascade mediated by endothelial
cells and cytokines [65, 66].
The Cytokine Network
Monocytic cells appear to have a pivotal role in mediation
of the biological effects of LPS (figure 2). First, LPS can be
removed from the blood and detoxified by monocytes-
events of benefit to the host [67]. Second, LPS-stimulated
monocytes produce cytokines such as TNF and IL-l. Several
binding sites for LPS on the macrophage surface have been
described [68]. LPS can also interact with monocytes after
binding to plasma molecules. An acute-phase protein called
LPS-binding protein (LBP) has been shown to bind to the
lipid A moiety ofLPS [69]. LPS-LBP is a ligand for the CD 14
receptors on monocytes and macrophages [70]. Further-
more, a soluble form ofthe CD 14 receptor in serum has been
shown to promote the binding of LPS to endothelial cells
and to stimulate these cells to produce cytokines and adhe-
sion molecules [71, 72]. The role played by soluble CD 14 in
vivo is still unknown. When complexed with LBP and at-
tached to monocytes, LPS can stimulate the production of
TNF by macrophages at concentrations far below those re-
quired for stimulation by LPS alone [69, 70, 73]. Recently,
another active component of human plasma, septin, has
been described; septin may share with LBP the capacity to
enhance the presentation of low concentrations of LPS to
monocytes [74]. This information suggests that recognition
of the presence ofLPS in plasma is important for an effective
response to infection with gram-negative bacteria. Therefore,
a principal function of LBP/septin may be to enhance the
ability of the host to detect LPS early in infection [69, 70,
74]. No information is available on the role ofLBP/septin or
CD 14 in vivo, but studies of the blocking ofLBP or CD 14 in
experimental models will help to define the early steps of
interaction of LPS and monocytes in the development of
shock.
Bactericidal/permeability-increasing protein (BPI), a pro-
tein that has significant amino acid sequence homology with
LBP (figure 2), appears to have therapeutic potential; it is
found in PMN azurophilic granules that bind to lipid A and
LPS in a way similar to that documented for LBP. BPI is an
antagonist of LBP because it inhibits rather than amplifies
the activity of LPS. In addition, BPI has been shown to in-
hibit the limulus lysate assay mediated by LPS or the LPS-
induced production of cytokines in blood [75, 76].
Experiments in animals challenged with endotoxin and
gram-negative bacteria are now planned with a cloned recom-
binant protein [77], and preliminary data on BPI-mediated
protection of mice challenged with LPS have been pre-
sented [78].
The intravascular activation of inflammatory systems in-
volved in septic shock is mainly the consequence ofan over-
production of various cytokines. Several cytokines are pro-
duced not only by macrophages but also by lymphocytes,
endothelial cells, and other cells stimulated by microbial
products. The systemic release oflarge amounts of cytokines
is associated with death from septic shock in humans [79-81 ].
TNF is regarded as a central mediator of the pathophysio-
logical changes associated with the release of LPS and possi-
bly with shock caused by microorganisms that do not contain
LPS. In animal models, antibodies to TNF-given either
prophylactically (before intravenous bolus injections of LPS
or gram-negative bacteria) or therapeutically (after chal-
lenge )-have effectively increased the rate of survival. A po-
tentially important advantage of making TNF (rather than
endotoxin) a target in intervention strategies in patients is its
possible role in the pathogenesis of shock caused by gram-
positive bacteria. For example, septicemia associated with
group A Streptococcus is clinically indistinguishable from
"classic" gram-negative septic shock [82]. Cell-free superna-
tants from cultures of gram-positive bacteria have been
shown to induce the release ofTNF from human peripheral-
blood monocytes in vitro [83], and concentrations ofTNF in
the serum of patients with gram-positive sepsis are as high as
those in the serum ofpatients with gram-negative sepsis [84].
However, antibodies to TNF have not been universally effec-
tive in models of gram-positive sepsis [85-87].
Cytokines other than TNF are involved in the induction of
a shock-like state in animals. Considerable interest has also
been focused on IL-I as a mediator of shock and of the asso-
ciated "acute-phase" responses [65]. Circulating levels ofIL-
I are elevated in shock; together with elevated levels ofTNF,
these increased levels of IL-I correlate with the severity of
disease. Direct proof of the central role of IL-l in septic
shock comes from experiments with animals in which spe-
cific blocking of the binding of IL-l to its cell receptor by
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IL-I ra prevented the detrimental effects of inoculation of
LPS or E. coli [88-90].
The overlap ofproinflammatory functions and the synergy
ofTNF and IL-l are probably important clues to the patho-
genesis of septic shock. The administration of low doses of
IL-l does not mediate severe shock and tissue injury; when
IL-l is combined with TNF, however, the former increases
the toxicity of the latter [91]. More important, LPS itself
potentiates the lethal effects of TNF [92]. Interferon 'Y has
also been implicated in the synergy of TNF and IL-I [93].
Since several cytokines are probably involved in the patho-
genesis of septic shock, blocking of TNF alone may not be
sufficient to reverse the relevant conditions; therefore, phar-
macotherapeutic "cocktails" may prove necessary.
The elucidation of these pathophysiological events has
prompted the development of strategies to counteract exces-
sive production or release of TNF and IL-I and hence to
prevent or treat septic shock. Many studies have indicated
that such therapy is beneficial in animals (including mice,
rats, pigs, rabbits, and baboons). However, other important
observations regarding potential therapeutic strategies must
be considered. First, TNF, IL-l, and other cytokines are re-
leased into the bloodstream during the first hour after bolus
injection of LPS or live bacteria; TNF disappears rapidly
from the circulation thereafter-several hours before the ani-
mal's death [94]. An identical pattern has been found in
children with fulminant meningococcemia [80]. Should it be
documented in most cases of septic shock in humans, this
pattern would suggest that levels of TNF may be elevated
before shock develops. If so, then perhaps antibodies to TNF
could not be administered soon enough to effectively treat
patients with full-blown shock.
Moreover, intravenous bolus challenge in animal models
and the fulminant course of meningococcal septicemia in
children may not reflect most of the clinical situations in
which septic shock develops. In most typical cases, a focus of
infection may be present for hours or days and may cause the
release of LPS or bacteria to be more sustained and subacute
than during fulminant shock. Indeed, when serum concen-
trations ofTNF and other cytokines were measured prospec-
tively in 70 patients with septic shock, levels of TNF and
IL-l were rather low and were detectable for up to 10 days
after the onset of shock in patients who ultimately died [81].
These results indicate that concentrations ofTNF and other
cytokines are sustained in patients presenting with gram-ne-
gative shock-a picture unlike that seen after LPS or bacte-
rial challenge in animal models, in which these concentra-
tions are elevated and transient. Moreover, experimental
models of severe, subacute, focal gram-negative bacterial in-
fection have exhibited a pattern of TNF release different
from that observed after bolus injection, and antibodies to
TNF have failed to prevent death in these models [95-97].
Thus the release ofTNF in most clinical cases ofseptic shock
is probably different from that in fulminant gram-negative
infections, and anticytokine therapies should be devised ac-
cordingly.
In such anticytokine therapies, the role of cytokines as a
defense against infection must be taken into account. TNF,
IL-I, and other cytokines participate in the defense of the
host; they are mediators that increase natural resistance by,
for example, upregulating the cytolytic activity of lympho-
cytes and the expression of complement receptors, enhanc-
ing the oxidative burst of neutrophils, activating macro-
phages, and stimulating the proliferation of B cells, T cells,
and progenitor cells. Indeed, while mice rendered deficient
in the 55-kD receptor for TNF became resistant to challenge
with endotoxin, they meanwhile became extremely sensitive
to infection with Listeria monocytogenes [98]. Thus the
blocking of cytokines in patients with septic shock for the
purpose of counteracting "harmful" concentrations may in-
terfere with the control of infection by physiological concen-
trations. As a result, the infections causing septic shock may
worsen, or the patient may become more susceptible to sec-
ondary infections.
Two major clinical studies of the blocking ofcytokines are
in progress, the first examining a murine antibody to TNF
and the second evaluating IL-I ra. Preliminary results indi-
cate that anticytokine reagents may have detrimental effects
in SUbgroups of patients; however, it is not known whether
the failure observed in patients not presenting with shock is
due specifically to a deleterious effect of these reagents on
the host defenses against intracellular pathogens. When fur-
ther results become available, the cause of the deaths of pa-
tients in the various SUbgroups will be analyzed.
The large-scale clinical trial of murine antibody to TNF
was initiated in patients presenting with sepsis syndrome and
septic shock. While interim analyses revealed a beneficial
(although statistically insignificant) effect of treatment on
mortality among patients with septic shock, a deleterious ef-
fect was found in some patients with sepsis syndrome [99]-
a less classic form of the cascade ofevents that leads to death
from infection. As a result, this study was discontinued, and
a new trial of antibody to TNF including only patients with
septic shock is being planned.
The results of the phase 3 trial of IL-I ra have recently
been presented [100]. This randomized, double-blind, pla-
cebo-controlled, multicenter clinical trial included 901 pa-
tients with sepsis syndrome and septic shock. At enrollment,
patients were randomized to receive either an intravenous
loading dose of IL-l ra (100 mg) or placebo, which was fol-
lowed by a continuous 72-hour intravenous infusion of IL-
Ira (1 mg/[kg· h] or 2 mg/[kg· h]) or placebo. Patients were
evaluated at 28 days for all-cause mortality. Treatment with
IL-l ra did not significantly improve the rate of survival,
which was the primary end point of the study. However, an
individual patient/risk assessment approach, which took into
account the APACHE III classification system and specific
risk factors for sepsis, was used to analyze outcome as a sec-
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ondary end point [101]. With this new method ofrisk predic-
tion, treatment with IL-l ra appeared to be beneficial for pa-
tients with a mortality risk of >0.24 but not for those with a
mortality risk of <0.24.
Both of these studies aimed at inhibiting cytokines. The
results suggest that, while this approach may be useful for the
most severely affected patients, it is potentially harmful to
patients who are less severely affected. Obviously, these find-
ings need to be confirmed, and the subgroup of patients who
might benefit from these therapies needs to be precisely de-
lineated. The results of the IL-l ra study suggest that defining
the risk of death at the time of intervention-rather than at
the time of clinical presentation-may be a simple tool for
identifying such patients.
Soluble forms of cytokine receptors offer an alternative
approach to the blocking of cytokines. The potential of this
approach was shown in experiments and clinical studies with
IL-l ra: soluble TNF receptors may also be of value (figure
2). These receptors inhibit the bioactivity of TNF in vivo
[102, 103]. Furthermore, it has recently been shown that
mice deficient in the 55-kD TNF receptor are resistant to
endotoxic shock [98]. Clinical trials with soluble TNF recep-
tors are therefore being planned.
Currently, two other cytokines, IL-8 and IL-I 0, are being
evaluated as possibly important mediators in shock. IL-8 has
been characterized primarily as a PMN chemoattractant and
a proinflammatory mediator; it has been detected in healthy
volunteers after intravenous injection of endotoxin [104]
and in patients with gram-negative shock [105]. Its precise
role in vivo has not yet been fully elucidated. Recently, the
anti-inflammatory IL-IO has been suggested as a candidate
for treatment of bacterial sepsis. IL-l 0 was found to decrease
the production of IL-l, IL-6, and TNF in vitro and to sup-
press cytokines and provide protection in mice challenged
with lethal doses of endotoxin [106, 107]. It is interesting
that protection was documented when the administration of
IL-IO was delayed after LPS challenge-an effect that is
hardly evident with antibodies to TNF. To investigate the
potential of IL-l 0 as a candidate for the treatment of bacte-
rial sepsis, these preliminary results in endotoxemia should
now be extended to bacterial infections.
Finally, as has been mentioned, the synergy that exists
among cytokines (especially TNF and IL-I) and between
cytokines and cell wall fragments (mainly TNF and LPS)
suggests that a combined approach aimed at blocking various
triggers and mediators may have the greatest potential for
improving the outcome of septic shock.
Conclusion
Several approaches to the treatment and prevention of
septic shock that are now being considered aim to suppress
and/or inhibit one or another of a range of cytokines and
other inflammatory mediators. However, since the syndrome
most likely results from complex interactions involving all
these pathways and cytokines, the roles that each mechanism
plays in the pathogenesis of septic shock must be delineated.
This information will help to identify the subsets of patients
who might benefit from the administration of antibodies to
endotoxin and cytokines and to ascertain the need for other
cytokine inhibitors or anti-inflammatory agents.
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